Design, Synthesis and Discovery of Picomolar Selective α4β2 Nicotinic Acetylcholine Receptor Ligands
Citations Over TimeTop 23% of 2013 papers
Abstract
Developing novel and selective compounds that desensitize α4β2 nicotinic acetylcholine receptors (nAChRs) could provide new effective treatments for nicotine addiction, as well as other disorders. Here we report a new class of nAChR ligands that display high selectivity and picomolar binding affinity for α4β2 nicotinic receptors. The novel compounds have Ki values in the range of 0.031-0.26 nM and properties that should make them good candidates as drugs acting in the CNS. The selected lead compound 1 (VMY-2-95) binds with high affinity and potently desensitizes α4β2 nAChRs. At a dose of 3 mg/kg, compound 1 significantly reduced rat nicotine self-administration. The overall results support further characterizations of compound 1 and its analogues in preclinical models of nicotine addiction and perhaps other disorders involving nAChRs.
Related Papers
- → Design, Synthesis and Discovery of Picomolar Selective α4β2 Nicotinic Acetylcholine Receptor Ligands(2013)15 cited
- → The Regulation of Hippocampal Nicotinic Acetylcholine Receptors (nAChRs) After a Protracted Treatment with Selective or Nonselective nAChR Agonists(1999)14 cited
- → In Silico Analysis of Ethanol Binding Activity in Neuronal Nicotinic Acetylcholine Receptors(2020)2 cited
- → Ganglionic nAChRs and high‐affinity nicotinic binding sites are not equivalent(1986)29 cited
- Synthesis and ~(125) I labeling of a precursor for imaging nicotinic acetylcholine receptors(2006)